UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 10, 2003
XOMA LTD.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
BERMUDA
--------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-14710 52-2154066
------------------------------------- ---------------------------------------
(Commission File Number) (IRS Employer Identification No.)
2910 Seventh Street, Berkeley, California 94710
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code (510) 204-7200
-----------------------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events
As announced on October 10, 2003, XOMA Ltd. has discontinued development of
MLN2201, a humanized monoclonal antibody being developed for conditions related
to inflammation of the heart and blood vessels. MLN2201 was one of two products
of an ongoing development collaboration with Millennium Pharmaceuticals, Inc.
A copy of the press release is attached hereto as Exhibit 1 and is
incorporated herein by reference.
Item 7. Exhibits
1. Press Release dated October 10, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: October 10, 2003 XOMA LTD.
By: /s/ Christopher J. Margolin
----------------------------------
Christopher J. Margolin
Vice President, General
Counsel and Secretary
EXHIBIT INDEX
Number Description
------ -----------
1. Press Release dated October 10, 2003.